SCHEMBL17130325

SCHEMBL17130325

NCCNc1nc(Nc2cccc(O)c2)nc(Nc2ccc(O)c3ccccc23)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 4/20 0.53
▸ TAAR1 Q96RJ0 1/20 0.47
▸ CDC25B P30305 1/20 0.44
▸ KMT2A Q03164 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ RAD52 P43351 1/20 0.41
▸ GFER P55789 1/20 0.41
▸ RECQL P46063 2/20 0.41
▸ MCL1 Q07820 1/20 0.41
▸ SYK P43405 3/20 0.40
▸ FCGR3B O75015 1/20 0.40
▸ FCGR1A P12314 1/20 0.40
▸ FCGR2A P12318 1/20 0.40
▸ KCNH3 Q9ULD8 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18385065 0.89 KCNH3 (0.46) IDO1TAAR1KCNH3
SCHEMBL25830630 0.89 KCNH3 (0.46) IDO1TAAR1KCNH3
SCHEMBL18391971 0.85 CDC25B (0.48) TAAR1CDC25BKMT2AMEN1POLB
SCHEMBL18391969 0.84 KCNH3 (0.58) TAAR1KMT2AMEN1RECQLMCL1
SCHEMBL13223236 0.82 CDC25B (0.48) TAAR1CDC25BKMT2AMEN1POLB
SCHEMBL12387589 0.82 SYK (0.48) TAAR1CDC25BKMT2AMEN1POLB
SCHEMBL17130323 0.82 CDC25B (0.45) TAAR1CDC25BKMT2AMEN1POLB
SCHEMBL18385063 0.76 EGFR (0.43) EGFR
SCHEMBL17130308 0.76 EGFR (0.43) EGFR
SCHEMBL13936066 0.74 FCGR3B (0.61) KMT2AMEN1POLBGFERRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11701429-B2 Targeted drug delivery through affinity based linkers Akamara Therapeutics, Inc. (US) 2023-07-18 — — US disclosed
US-11701429-B2 Targeted drug delivery through affinity based linkers Akamara Therapeutics, Inc. (US) 2023-07-18 — — US disclosed
US-20200199249-A1 TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS Akamara Therapeutics, Inc. (US) 2020-06-25 — — US disclosed
US-10533059-B2 Targeted drug delivery through affinity based linkers Akamara Therapeutics, Inc. (US) 2020-01-14 — — US disclosed
US-20170014528-A1 TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS INVICTUS ONCOLOGY PVT. LTD. (IN) 2017-01-19 — — US disclosed
US-20170014528-A1 TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS INVICTUS ONCOLOGY PVT. LTD. (IN) 2017-01-19 — — US disclosed
WO-2015148126-A1 TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS INVICTUS ONCOLOGY PVT. LTD. (IN) 2015-10-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170014528-A1 TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS ABCG2, ADAM8, TIE1 IDO1 3682/4885TAAR1 2020/4885CDC25B 2257/4885
US-11701429-B2 Targeted drug delivery through affinity based linkers ABCG2, FCGR2A, ABCB1 IDO1 3948/4885TAAR1 1689/4885CDC25B 2120/4885
US-20200199249-A1 TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS ABCG2, FCGR2A, ABCB1 IDO1 3948/4885TAAR1 1689/4885CDC25B 2120/4885
US-10533059-B2 Targeted drug delivery through affinity based linkers ABCG2, ADAM8, TIE1 IDO1 3682/4885TAAR1 2020/4885CDC25B 2257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback